Form 4: Cocrystal Pharma Director Boosts Stake

Cocrystal Pharma's Director and 10% owner, Phillip Frost MD, acquired 359,713 common shares and 719,426 warrants through an indirect trust.

Summary

• Phillip Frost MD, a Director and 10% owner of Cocrystal Pharma, Inc. (COCP), acquired additional securities on October 28, 2025.
• The acquisition involved 359,713 units at $1.39 per unit, with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock.
• This resulted in the acquisition of 359,713 shares of common stock and 719,426 warrants.
• The warrants have an exercise price of $1.24 per share and expire on January 28, 2028.
• Following the transaction, beneficial ownership includes 1,679,551 common shares held indirectly by Frost Gamma Investments Trust and 27,100 common shares held directly.
• The warrants are also held indirectly by Frost Gamma Investments Trust.
• The acquisition was approved by a Special Committee of the Board of Directors, consisting of two non-employee directors, making it exempt from Section 16(b) of the Securities Exchange Act of 1934.

Sentiment

Score: 8

Explanation: Strong insider buying by a key director and 10% owner, coupled with board approval, suggests high confidence in the company's prospects. The acquisition of warrants further amplifies this positive signal, indicating a belief in significant future upside.

Positives

• Significant insider buying by a Director and 10% owner, indicating strong confidence in the company's future prospects.
• The transaction was approved by a Special Committee of independent directors, ensuring proper corporate governance and oversight.
• The acquisition of warrants provides additional leveraged upside potential for the insider, aligning their interests with long-term shareholder value.

Future Outlook

NA

Management Comments

• The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Industry Context

This insider purchase by a significant shareholder and director in a biotechnology company like Cocrystal Pharma could signal confidence in the company's drug development pipeline or future prospects, especially given the capital-intensive nature of the pharmaceutical industry. Such transactions are often closely watched by investors for insights into management's perception of intrinsic value.

Corporate Governance

Related Party Transactions

• The transaction involves a Director and 10% owner, Phillip Frost MD, acquiring securities from the issuer, which constitutes a related-party transaction.
• The transaction was approved by a Special Committee of the Board of Directors to ensure fairness and compliance with regulatory requirements.

Stakeholder Impact

• Shareholders: Potential positive signal due to significant insider confidence, which could lead to increased investor interest and potentially a positive impact on share price.
• Company: Received capital infusion from the transaction, strengthening its financial position, and further aligning the interests of a key director and major shareholder with the company's performance.

Key Dates

Recommendation

The significant acquisition of common stock and warrants by a Director and 10% owner, Phillip Frost MD, signals strong conviction in Cocrystal Pharma's future. This insider buying, especially with board approval, suggests that management believes the stock is undervalued or expects positive developments. For a seasoned investor, this action provides a strong bullish indicator, warranting a 'buy' recommendation.

Keywords

Cocrystal Pharma, COCP, Phillip Frost, Insider Buying, Form 4, Stock Acquisition, Warrants, Biotechnology, Pharmaceuticals, Director Ownership, 10% Owner